Your search for smoking cessation returned 33 results

The FDA determined the benefits of this smoking cessation therapy outweighed the potential risks.

According to a study in Nicotine & Tobacco Research, the relative coronary heart disease (CHD) risk is greater for smokers who consume cigarettes over a longer period of time vs. smokers who consume the same quantity over a shorter period.

In a first-ever prospective study evaluating lorcaserin in reducing post-cessation weight gain in overweight and obese smokers, researchers found that lorcaserin combined with varenicline minimized weight gain and increases in waist circumference.

Cigarette smoking may blunt the renal protective effects of drugs taken by patients with early chronic kidney disease.

According to new research published in The Journal of Infectious Diseases, smoking may actually decrease an HIV patient’s lifespan more than the virus itself.

At a joint meeting of the Food and Drug Administration (FDA)’s Psychopharmacologic Drugs Advisory Committee and Drug Safety Risk Management Advisory Committee, a majority vote recommended the removal of the boxed warning regarding serious neuropsychiatric adverse events from the Chantix (varenicline; Pfizer) labeling.

Data from a pilot randomized trial published in Nicotine & Tobacco Research showed that administering exogenous progesterone may potentially prevent postpartum smoking relapse.

The Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for bupropion extended-release products.

According to a study in The American Journal of Drug and Alcohol Abuse, psilocybin showed promise in promoting long-term smoking abstinence in the context of a structured treatment program.

According to a study published in the British Journal of Cancer, a common medication for breast cancer may have reduced efficacy in patients who smoke vs. non-smokers.